None listed
Conditions
Interventions
Medical Device : After achieving stable hemodynamics and pseudo-steady-state anaesthetic drug concentrations, ipratropium bromide was administered using a nebulizer, and 0.5 mg ipratropium bromide was
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Patients scheduled for elective surgery under general anesthesia • American Society Anesthesiologists Physical Status (ASA PS) 1, 2 or 3 • Aged 20 years or above • Position during operation: supine position • Forced expiratory volume in 1 second (FEV1) < 80% • FEV1 (forced expiratory volume in1 second) /FVC (forced vital capcaity) < 80%
Exclusion criteria
Exclusion criteria: • History of lung resection surgery • Patients unable to perform pulmonary function test • Active respiratory symptoms such as wheezing, respiratory infection • History of ischemic heart disease, congestive heart failure and myocardial infarction • History of liver disease such as hepatitis and liver cirrhosis • History of chronic renal failure • History of glaucoma • History of benign prostatic hyperplasia • Position during operation: prone position • AST (aspartate aminotransferase)> 80 IU/L - ALT (alanine aminotransferase)> 80 IU/L • Estimated glomerular filtrattion rate (GFR) < 60 • Patients who administered ipratropium bromide within 48 h before the entrance to an operation room • Allergy to ipratropium bromide • Evidence of pregnancy • Hemoglobin < 10 g/dl • Unable or unwilling to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| dose normalized area under the curve | — |
Secondary
| Measure | Time frame |
|---|---|
| safety | — |
Countries
Korea, Republic of
Contacts
Public Contactbyungmoon choi
Asan Medical Center
Outcome results
None listed